When a dose step is not going well: what the labels say about slowing down, staying put and stepping back

Every escalation schedule looks tidy on paper: a new dose every four weeks until the maintenance dose, done. Real weeks are messier. A step lands badly, the nausea does not settle, a holiday or an illness intervenes, or the person simply does not want to go higher. The labels anticipate more of this than most people are told. This guide sets out exactly what they permit, exactly what they do not, and how to take the question to a prescriber.

The schedules as written

Wegovy. The label's Table 1: 0.25 mg once weekly for weeks 1 to 4, 0.5 mg for weeks 5 to 8, 1 mg for weeks 9 to 12, 1.7 mg for weeks 13 to 16, then 2.4 mg from week 17 as the maintenance dose. The purpose stated on the label is to reduce the risk of gastrointestinal adverse reactions. The label also describes a higher 7.2 mg regimen studied more recently; it is outside the scope of this guide.

Zepbound. 2.5 mg once weekly for 4 weeks, then 5 mg. Further increases in 2.5 mg increments after at least 4 weeks on the current dose. Maintenance doses are 5, 10 or 15 mg; the maximum is 15 mg. The label says the 2.5 mg dose is for treatment initiation and is not approved as a maintenance dosage.

Ozempic and Mounjaro follow the same shapes for their diabetes indications, with Ozempic's steps at 0.25, 0.5, 1 and 2 mg.

Note the phrase "at least 4 weeks" in the Zepbound label and the 4-week blocks in Wegovy's table. Four weeks is a minimum on a step, not a maximum.

What the labels permit when a step is not tolerated

Delay the next step. Wegovy: "If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks." Zepbound's "at least 4 weeks" language leaves the length of each step open. Staying eight weeks on a step instead of four is on-label for both.

Settle at a lower maintenance dose. Zepbound: "Consider treatment response and tolerability when selecting the maintenance dosage. If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage." Five milligrams is a maintenance dose on the label, not a way-station. In SURMOUNT-1 (Jastreboff 2022, PubMed 35658024), the 5 mg arm lost a mean of 15 percent of body weight over 72 weeks, against 19.5 percent at 10 mg and 20.9 percent at 15 mg. The lowest maintenance dose delivered most of the effect.

Step down. Wegovy: if the 2.4 mg maintenance dose is not tolerated, the dose can be decreased to 1.7 mg once weekly, with re-escalation to 2.4 mg to be considered later. That is a label-sanctioned step backward.

Reinitiate after a gap. Wegovy: if two or more consecutive doses are missed, reinitiate dose escalation at a lower dosage to reduce the risk of GI adverse reactions. The label does not specify which lower dose; the prescriber does.

What the labels do not permit

Staying on the starting dose as maintenance. Zepbound's label is explicit that 2.5 mg is not approved for maintenance; Wegovy's table treats 0.25 mg the same way. A prescriber can decide to hold someone on an initiation dose for longer, and that is their clinical judgement, but it is not what the label describes.

Stretching the interval. Every label says once weekly. The labels give a minimum gap between doses (72 hours for Zepbound and Mounjaro, 48 hours for Wegovy and Ozempic) for changing the injection day, not a maximum; a dose "every ten days" is simply repeated late doses, each one landing in or past the missed-dose window, and it is not a studied regimen.

Splitting a pen. The single-dose pens deliver a fixed dose and cannot be partially used. The multi-dose KwikPen and FlexTouch dial only the labelled doses. Half-doses are not a labelled option for any pen.

Skipping steps upward. The Zepbound label requires at least 4 weeks on a dose before increasing. Jumping from 5 to 10 mg in two weeks because the 5 mg felt fine is not on the label, and the label's own reason for the schedule is GI tolerability.

Self-adjusting. None of the above is a decision for the person injecting. All of it is a prescriber decision, informed by what you report.

Recognising a step that is not going well

Nausea, vomiting, diarrhoea or constipation that is worse in the second and third weeks of a step than the first, rather than easing. Being unable to eat enough to reach a reasonable protein intake (the muscle guide explains why that matters). Losing weight faster than you and your prescriber intended. Dehydration signs (see the hydration guide). Fatigue, dizziness or low mood that arrived with the step. Any of the label's warning-sign symptoms, which are not tolerability problems but reasons to be assessed: severe persistent abdominal pain, right upper abdominal pain with fever or jaundice, vomiting you cannot control.

Compare with the label pattern: GI reactions mostly during escalation, mostly mild to moderate, mostly transient. A step that fits that pattern and is easing by week three is going as the label predicts. A step that is not easing is the situation the label's tolerability options were written for.

How to raise it

Do it before the next scheduled increase, not after the next pen has been dispensed. Bring numbers: how many days of nausea in each of the last three weeks, how many vomits, weight change over the step, what you have managed to eat. The clinical-practice recommendations (Wharton 2022, PubMed 34775881) describe exactly this kind of structured report as what lets a prescriber choose between delaying, holding and stepping down.

Ask specifically: "The label allows delaying escalation by four weeks. Can we do that?" or "The label lists 5 mg as a maintenance dose. Can I stay here?" Naming the label option changes the conversation from a complaint into a choice between labelled alternatives. The prescriber checklist has these questions written out.

If your prescription is dispensed as a titration pack or an auto-shipped sequence, ask the pharmacy or program to pause the next strength until the prescriber has decided. Injecting the next strength because it arrived is the commonest way an unwanted step happens.

Illness, holidays and interruptions

A stomach bug in the middle of a step is two causes of vomiting at once; most prescribers would rather you rode out the illness on the current dose than stepped up on schedule. A missed dose during travel triggers the missed-dose rules (Zepbound within 4 days, Wegovy if the next dose is more than 2 days away, Ozempic within 5 days) and does not by itself reset the escalation; two consecutive missed Wegovy doses do, per the label. Tell the prescriber about any gap longer than one dose before restarting.

Compounded products

Compounded semaglutide and tirzepatide are not FDA approved and are not interchangeable with brand products, and a compounded prescription may follow a schedule that differs from the label tables above, including strengths that do not exist as brand doses. The label options (delay, hold, step down) are still the framework a prescriber will reason from. Two compounding-specific checks belong in any tolerability conversation: that the concentration on the current vial matches the one you are calculating from, and that the volume you draw matches the prescribed milligrams, using the dose unit converter. A "bad step" is sometimes a dosing error. FormBlends describes what its pharmacies dispense on its semaglutide and tirzepatide pages.